LONDON, September 20, 2018 /PRNewswire/ --
The ICEfx™ Cryoablation system is a
compact and powerful console, offering predictable, reliable
performance with seamless therapy delivery and exceptional ease of
technical operation
BTG plc (LSE: BTG), a global specialist healthcare company,
today announced the global launch of the ICEfx™ Cryoablation
System. ICEfx™, an evolution of the existing Visual ICE™ system,
offers predictable, reliable performance with seamless therapy
delivery and exceptional ease of technical operation. This
compact and powerful console is designed for interventional
radiologists who want to offer their patients state-of-the-art,
minimally invasive treatment options.
(Logo:
https://mma.prnewswire.com/media/513730/BTG_IO_Logo.jpg )
It allows physicians to provide safe and efficient cryoablation
procedures, facilitating precise and effective treatment without
the need for surgery or repeated radiation treatments.
"The ICEfx™ Cryoablation System is a new, more compact design
that simplifies the procedure through a set of user-friendly
on-screen prompts" said Dr. AJ Gunn, Interventional Radiologist at
University of Alabama, Birmingham.
"It is easy for my technicians to set up, operate, and shut
down. Importantly, this updated version is designed to work
with the current line of BTG cryoablation probes, meaning that
physicians can still create the reliable ablation zones they have
come to expect."
Peter Pattison, Head of
Interventional Oncology at BTG commented: "We continue to invest in
both new product innovations and clinical research. Building
on our commitment in Interventional Oncology, BTG has added the
most advanced cryoablation technology to its portfolio of minimally
invasive therapies and is currently supporting a number of active
clinical research studies in bone, kidney, lung, pain and prostate.
We strive to provide health care professionals with easy
access to innovative product choices, our BTG IO portfolio allows
them to select and tailor each clinical solution to match a
specific patient need."
The ICEfx™ Cryoablation system will be launched at The
Cardiovascular and Interventional Radiological Society of
Europe (CIRSE) meeting from
22-25 September 2018 in Lisbon, Portugal.
About BTG IO Ablation
(Cryoablation)
BTG Interventional Oncology is a global leader in delivering
innovative IO Ablation solutions. Our cryoablation products address
patient conditions across multiple physician specialties. Treatment
areas and clinical research priorities include conditions affecting
bone, kidney, liver, lung and prostate, as well as targeted pain
and nerve applications.
Not all indications are for all the geographies. For a
full list of indications, instructions for use and important safety
information, please visit www.ioablation.com.
About BTG Interventional Oncology
BTG Interventional Oncology is transforming the way cancer is
treated with wide-ranging solutions consisting of
minimally-invasive, highly targeted therapies that can be
personalised to each patient's needs. Our products are used to
treat or provide symptomatic relief for people with cancer and
benign tumours. To learn more about BTG Interventional Oncology,
please follow @BTGIO on Twitter or visit btg-io.com
For further information contact:
BTG plc
Chris Sampson, Corporate
Communications Director
Tel: +44-20-7575-1595
Mobile: +44-7773-251-178
SOURCE BTG plc